Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alfa 5 for Chronic Hepatitis C
NCT01121731Phase 2Completed
- Sponsor
- Digna Biotech S.L.
- Start
- May 2010
- Primary completion
- Oct 2012
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-5 in hepatitis C (HCV) (3 arms), sponsored by Digna Biotech S.L. Primary endpoint: Safe dose level at 29 days. Started May 2010; status: completed.
02
Drugs
interferon alfa-5
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01121731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121731.